

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

Animal Models of *N*-Methyl-*N*-nitrosourea-induced Mammary Cancer and Retinal Degeneration with Special Emphasis on Therapeutic Trials. A. TSUBURA, Y.-C. LAI, H. MIKI, T. SASAKI, N. UEHARA, T. YURI, K. YOSHIZAWA (*Osaka, Japan*)

Intraesophageal Administration of GS-Nitroxide (JP4-039) Protects Against Ionizing Irradiation-induced Esophagitis. M.W. EPPERLY, J.P. GOFF, S. LI, X. GAO, P. WIPF, T. DIXON, H. WANG, D. FRANICOLA, H. SHEN, J.-C.M. RWIGEMA, V. KAGAN, M. BERNARD, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effects of Combined Insulin-like Growth Factor 1 and Macrophage Colony-stimulating Factor on the Skeletal Properties of Mice. S.A. LLOYD, S.J. SIMSKE, L.K. BOGREN, S.E. OLESIAK, T.A. BATEMAN, V.L. FERGUSON (*Hershey, PA; Boulder; Fort Collins, CO; Chapel Hill, NC, USA*)

Cell Death Detection after High-LET Irradiation in an Orthotopic Human Hepatocellular Carcinoma *in Vivo*. A. ALTMAYER, M. IGNAT, J.-M. DENIS, N. MESSADDEQ, J. GUEULETTE, D. MUTTER, P. BISCHOFF (*Strasbourg; Illkirch Graffenstaden, France; Brussels, Belgium*)

Serum Calcium-decreasing Factor, Caldecrin, Ameliorates Muscular Dystrophy in *dy/dy* Mice. M. TOMOMURA, T. FUJII, H. SAKAGAMI, A. TOMOMURA (*Saitama; Tokushima, Japan*)

Nitric Oxide Concentrations are Normal and Unrelated to Activity Level in Chronic Fatigue Syndrome. M. MEEUS, I. VAN EUPEN, J. HONDEQUIN, L. DE HAUWERE, D. KOS, J. NIJS (*Antwerpen; Brussel, Belgium*)

Gene Expression Analysis of Oxidative Stress and Apoptosis in Proton-irradiated Rat Retina. X.W. MAO, L.M. GREEN, T. MEKONNEN, N. LINDSEY, D.S. GRIDLEY (*Loma Linda, CA, USA*)

Colon Cancer Vaccines: An Update. E. MERIKA, M.W. SAIF, A. KATZ, K. SYRIGOS, M. MORSE (*London, UK; Haven, CT; Durham, NC, USA; Athens, Greece*)

Novel Microminipig Model of Atherosclerosis by High Fat and High Cholesterol Diet, Established in Japan. N. MIYOSHI, M. HORIUCHI, Y. INOKUCHI, Y. MIYAMOTO, N. MIURA, S. TOKUNAGA, M. FUJIKI, Y. IZUMI, H. MIYAJIMA, R. NAGATA, K. MISUMI, T. TAKEUCHI, A. TANIMOTO, N. YASUDA, H. YOSHIDA, H. KAWAGUCHI (*Kagoshima; Osaka, Japan*)

CD95 and TNF α -induced Apoptosis in Liver Metastases of Colorectal Carcinoma. H.-U. KASPER, E. KONZE, M. KERN, D.L. STIPPEL (*Münster; Köln; Heidelberg, Germany*)

Thrombogenicity of Sirolimus-eluting Stents and Bare Metal Stents: Evaluation in the Early Phase after Stent Implantation. T. WALTER, K.S. REY, H.P. WENDEL, S. SZABO, T. SUSELBECK, C.-E. DEMPFLER, M. BORGGREFE, S. SWOBODA, M.E. BEYER, H.M. HOFFMEISTER (*Mannheim; Kirchheim; Tuebingen; Solingen, Germany*)

Non-antibiotics Reverse Resistance of Bacteria to Antibiotics. J.E. KRISTIANSEN, V.F. THOMSEN, A. MARTINS, M. VIVEIROS, L. AMARAL (*Odense; Copenhagen, Denmark; Lisbon, Portugal*)

An Adult Myometrial Pluripotential Precursor that Promotes Healing of Damaged Muscular Tissues. B.G. GALVEZ, N.S. MARTÍN, P. SALAMACOHEN, J.J. LAZCANO, M.J. CORONADO, M.L. LAMELAS, A. ALVAREZ-BARRIENTES, N. EIRÓ, F. VIZOSO, C. RODRIGUEZ (*Gijón, Spain*)

A Possible Mechanism for Altered Immune Response in the Elderly. G. MAZZOCOLI, A. DE CATA, S. CARUGHI, A. GRECO, M. INGLESE, F. PERFETTO, R. TARQUINI (*San Giovanni Rotondo; Florence, Italy*)

Urine and Serum Analysis of Consumed Curcuminoids Using an I κ B-luciferase Surrogate Marker Assay. S. PONNURANGAM, F.G. MONDALEK, J. GOVIND, D. SUBRAMANIAM, C. HOUCHEM, S. ANANT, P. PANTAZIS, R.P. RAMANUJAM (*Oklahoma City, OK, USA*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS

www.iiar-anticancer.org, www.iiarjournals.org

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004), VOL. 2 (2005), VOL. 3 (2006), VOL. 4 (2007),
VOL. 5 (2008), VOL. 6 (2009), VOL. 7 (2010), VOL. 8 (2011)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our websites www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iia-anticancer.org (Editorial Office); IAR websites: www.iia-anticancer.org and www.iia-journals.org

Free specimen copies of CGP are available on request.

A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNITSKYI (*Stockholm; Uppsala, Sweden; Chelmsford, UK; Olsztyn, Poland; Gold Coast, QLD, Australia*)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DU-QUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (*Columbia, SC; St. Louis, MO, USA*)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (*Munich, Germany*)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (*Norcross, GA, USA; Guangzhou, P.R. China*)

TGF- β 1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (*Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA*)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India*)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, J.-I. ISHII, K. MATSUMOTO, R. NAGASHIO, I. OKAYASU (*Kanagawa, Japan*)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O'MEARA, S. CRUET-HENNEQUART, M.P. CARTY (*Galway, Ireland*)

Identification of Melanoma Antigens Using a Serological Proteome Approach (SERPA). A. SUZUKI, A. IIZUKA, M. KOMIYAMA, M. TAKIKAWA, A. KUME, S. TAI, C. OHSHITA, A. KURUSU, Y. NAKAMURA, A. YAMAMOTO, N. YAMAZAKI, S. YOSHIKAWA, Y. KIYOHARA, Y. AKIYAMA (*Shizuoka; Tokyo; Saitama, Japan*)

DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S.ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (*Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA*)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRÜCK, G. PEREIRA, T. EFFERTH (*Heidelberg; Mainz, Germany*)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (*Regensburg; Munich, Germany*)

Expression of IGF-1 and IGF-1R and Their Relation to Clinicopathological Factors in Colorectal Cancer. I. SHIRATSUCHI, Y. AKAGI, A. KAWAHARA, T. KINUGASA, K. ROMEO, T. YOSHIDA, Y. RYU, Y. GOTANDA, M. KAGE, K. SHIROUZU (<i>Fukuoka, Japan</i>).....	2541
Relationship between Ulcerative Colitis Patients Treated with Leukocytapheresis and Ulcerative Colitis-associated Colorectal Cancer. T. KINUGASA, Y. AKAGI, K. MUROTANI, K. ROMEO, T. YOSHIDA, Y. RYU, I. SHIRATUCHI, K. SHIROUZU (<i>Fukuoka; Kobe, Japan</i>)	2547
Assessment of HB-EGF Levels in Peritoneal Fluid and Serum of Ovarian Cancer Patients using ELISA. S. HIKITA, F. YOTSUMOTO, T. FUMAKI, S. HORIUCHI, A. SANUI, K. MIYATA, S.O. NAM, H. TSUJIOKA, T. UEDA, K. SHIROTA, T. YOSHIZATO, K. MAEDA, T. ISHIKAWA, Y. OKUNO, M. KUROKI, E. MEKADA, S. MIYAMOTO (<i>Fukuoka; Osaka, Japan</i>)	2553
Efficiency of Antimicrobial Defense: Molecular Flexibility of Natural Defensin and Artificial <i>Bis</i> -quaternary Ammonium Compound. K. OHKURA, Y. SHINOHARA, H. HORI (<i>Suzuka, Mie; Tokushima, Japan</i>)	2561
* Reviews (pages 2413, 2425, 2431, 2437)	

Frequency of Myeloid Dendritic Cells Can Predict the Efficacy of Wilms' Tumor 1 Peptide Vaccination. S. OHNO, F. TAKANO, Y. OHTA, S. KYO, S. MYOJO, S. DOHI, H. SUGIYAMA, T. OHTA, M. INOUE (Tokyo; Ishikawa; Osaka, Japan)	2447
Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells. T. TSUNODA, Y. TAKASHIMA, Y. YOSHIDA, K. DOI, Y. TANAKA, T. FUJIMOTO, T. MACHIDA, T. OTA, M. KOYANAGI, M. KUROKI, T. SASAZUKI, S. SHIRASAWA (Fukuoka, Japan)	2453
A Possible Clinical Adaptation of CRM197 in Combination with Conventional Chemotherapeutic Agents for Ovarian Cancer. H. TSUJIOKA, T. FUKAMI, F. YOTSUMOTO, T. UEDA, S. HIKITA, Y. TAKAHASHI, H. KONDO, M. KUROKI, S. MIYAMOTO (Fukuoka, Japan)	2461
Functional Characterization of Lipopolysaccharide derived from Symbiotic Bacteria in Rice as a Macrophage-activating Substance. T. KADOWAKI, H. INAGAWA, C. KOHCHI, M. HIRASHIMA, G.-I. SOMA (Kagawa-ken, Yamaguchi-ken; Chiba-ken; Tokushima-ken, Japan)	2467
Design, Synthesis and Destructive Dynamic Effects of BODIPY-containing and Curcuminoid Boron Tracedrugs for Neutron Dynamic Therapy. E. NAKATA, M. KOIZUMI, Y. YAMASHITA, K. ONAKA, Y. SAKURAI, N. KONDO, K. ONO, Y. UTO, H. HORI (Tokushima; Osaka, Japan)	2477
Antitumor Effects of CRM197, A Specific Inhibitor of HB-EGF, in T-Cell Acute Lymphoblastic Leukemia. N. KUNAMI, F. YOTSUMOTO, K. ISHITSUKA, T. FUKAMI, T. ODAWARA, S. MANABE, T. ISHIKAWA, K. TAMURA, M. KUROKI, S. MIYAMOTO (Fukuoka; Osaka, Japan)	2483
Effect of the Gc-derived Macrophage-activating Factor Precursor (preGcMAF) on Phagocytic Activation of Mouse Peritoneal Macrophages. Y. UTO, S. YAMAMOTO, R. TAKEUCHI, Y. NAKAGAWA, K. HIROTA, H. TERADA, S. ONIZUKA, E. NAKATA, H. HORI (Tokushima; Tokyo; Chiba; Nagasaki; Kyoto, Japan)	2489
Differential Expression of mRNA in Human Monocytes following Interaction with Human Colon Cancer Cells. T. HONDA, H. INAGAWA, I. YAMAMOTO (Kanagawa; Kagawa, Japan)	2493
Clinical Course of Colorectal Cancer in Patients with Ulcerative Colitis. D. HIGASHI, K. FUTAMI, Y. ISHIBASHI, Y. EGAWA, T. MAEKAWA, T. MATSUI, A. IWASHITA, M. KUROKI (Chikushino-shi; Fukuoka, Japan)	2499
Combinatorial Cytotoxicity of Gemcitabine and Cytokine-activated Killer Cells in Hepatocellular Carcinoma via the NKG2D-MICA/B System. T. MORISAKI, H. ONISHI, N. KOYA, A. KIYOTA, H. TANAKA, M. UMEBAYASHI, T. OGINO, I. NAGAMATSU, M. KATANO (Fukuoka, Japan)	2505
Novel Complementary Peptides to Target Molecules. H. OKADA, M. IMAI, F. ONO, A. OKADA, T. TADA, Y. MIZUE, K. TERAOKA, N. OKADA (Nagoya; Tsukuba; Sapporo, Japan)	2511
Decreased Expression of Claudin-1 in Rectal Cancer: A Factor for Recurrence and Poor Prognosis. T. YOSHIDA, T. KINUGASA, Y. AKAGI, A. KAWAHARA, K. ROMEO, I. SHIRATSUCHI, Y. RYU, Y. GOTANDA, K. SHIROUZU (Fukuoka, Japan)	2517
Sonodynamic Therapy with 5-Aminolevulinic Acid and Focused Ultrasound for Deep-seated Intracranial Glioma in Rat. T. OHMURA, T. FUKUSHIMA, H. SHIBAGUCHI, S. YOSHIZAWA, T. INOUE, M. KUROKI, K. SASAKI, S.-I. UMEMURA (Fukuoka; Miyagi, Saitama, Japan)	2527
KRAS-mediated Up-regulation of RRM2 Expression Is Essential for the Proliferation of Colorectal Cancer Cell Lines. Y. YOSHIDA, T. TSUNODA, K. DOI, Y. TANAKA, T. FUJIMOTO, T. MACHIDA, T. OTA, M. KOYANAGI, Y. TAKASHIMA, T. SASAZUKI, M. KUROKI, A. IWASAKI, S. SHIRASAWA (Fukuoka, Japan)	2535